Search Results

Moximed today announced that Christopher Gleason has been appointed President and Chief Executive Officer (CEO).

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced that Dave Amerson has joined the company’s Board of Directors.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced that James Leech has joined the company as Chief Financial and Strategy Officer.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced the first commercial cases of the MISHA™ Knee System, an implantable shock absorber for the knee.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced the publication of a peer-reviewed article of the MISHA™ Knee System, an implantable shock absorber (ISA) for the knee.

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit (OSET) in Boston.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced $40 million in Series C equity and debt financing.

Moximed will present key data from the pivotal study of the MISHA™ Knee System at the 12th Orthopaedic Summit (OSET). A presentation of the implantable shock absorber’s (ISA’s) design and clinical evolution will also be presented by Andreas H. Gomoll, MD, Professor of Orthopedic Surgery at the Hospital for Special Surgery in New York.

Moximed announced two new peer-reviewed publications reported additional supporting data for the MISHA™ Knee System, an implantable shock absorber for patients with osteoarthritis who are not ready for a knee replacement.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) granted marketing authorization of the MISHA™ Knee System, an implantable shock absorber (ISA) for the knee.